Targeted therapy of psoriasis: inhibition of the IL-23 signaling pathway — evidence from clinical studies and real practice
- Authors: Hotko A.A.1, Pomazanova M.Y.1, Kruglova L.2
-
Affiliations:
- Clinical dermatovenerologic dispensary of the Ministry of healthcare of Krasnodar region
- Central clinical hospital with polyclinic Department of Presidential Affairs
- Issue: Vol 96, No 4 (2020)
- Pages: 49-59
- Section: CLINICAL PRACTICE GUIDELINES
- URL: https://journals.rcsi.science/0042-4609/article/view/117518
- DOI: https://doi.org/10.25208/vdv1160-2020-96-4-49-59
- ID: 117518
Cite item
Full Text
Abstract
The article presents the results of clinical studies of the efficacy and safety of the use of a new drug of genetically engineered biological therapy guselkumab. Guselkumab is the first representative of the interleukin-23 (IL-23) inhibitor class and has a number of advantages over existing therapy.
According to direct comparative randomized clinical trials, guselkumab is superior in the short-term and, most importantly, in the long-term to most genetically engineered biologic drugs, including TNF-á inhibitors, secukinumab and ustekinumab.
In phase 3 studies (VOYAGE 1 and VOYAGE 2), the ECLIPSE study shows that guselkumab can achieve complete (PASI 100) and almost complete (PASI 90) skin cleansing by 16 weeks from the start of therapy in 37.4 and 73.3% of patients, respectively, with a subsequent increase in the proportion of patients with clean and almost clean skin by 24 weeks to 44.4 and 80.2%, respectively, and maintaining the achieved performance indicators for 4 years at the level of 51.7 and 84.0% respectively.
One of the potential advantages of IL-23 inhibitors is also the long-term maintenance of the achieved effect after treatment cessation. Guselkumab therapy is characterized by a favorable safety profile comparable to ustekinumab. During the follow-up period of patients in the course of randomized controlled trials of phase 3, data were obtained on the high safety of the drug and the absence of significant risks for serious infections, cardiovascular events, malignancies or suicidal tendencies. The drug is effective for insufficient response to adalimumab and ustekinumab.
The article presents 3 clinical cases of guselkumab use in patients with severe, including "problematic" psoriasis, comorbid pathology, with inefficiency or intolerance to systemic therapy, with secondary inefficiency of adalimumab. All patients managed to achieve a PASI of 90/100. No adverse events were observed.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Alkes A. Hotko
Clinical dermatovenerologic dispensary of the Ministry of healthcare of Krasnodar region
Email: alkes@inbox.ru
ORCID iD: 0000-0002-8688-4876
Russian Federation
Marina Yu. Pomazanova
Clinical dermatovenerologic dispensary of the Ministry of healthcare of Krasnodar region
Author for correspondence.
Email: mmm-marusya-mmm@mail.ru
ORCID iD: 0000-0003-0122-5319
заведующая женским стационарным отделением
Russian FederationLarisa Kruglova
Central clinical hospital with polyclinic Department of Presidential Affairs
Email: kruglovals@mail.ru
ORCID iD: 0000-0002-5044-5265
Russian Federation
References
- Потекаев Н.Н., Круглова Л.С. Псориатическая болезнь. М., 2014;264 c. [Potekaev N.N., Kruglova L.S. Psoriatic disease. M., 2014;264 р. (In Russ).]
- Abuabara K. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the United Kingdom. Br J Dermatol. 2010;163(3):586–592.
- Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76:377–90.
- Van de Kerkhof PC, Reich K, Kavanaugh A, Bachelez H, Barker J, Girolomoni G, Langley RG, Paul CF, Puig L, Lebwohl. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. J Eur Acad Dermatol Venereol. 2015;29(10).
- Насонов Е.Л. Ревматология: клинические рекомендации. М.: ГЭОТАР-Медиа. 2010;752 c. [Nasonov EL. Rheumatology: clinical guidelines. M.: GEOTAR-Media, 2010;752 р. (In Russ).]
- Кубанова A.A. Иммунные механизмы псориаза. Новые стратегии биологической терапии // Вестник дерматологии и венерологии. 2010;№1:35–47. [Kubanova AA. Immune mechanisms of psoriasis. A new strategy for biological treatment // Vestnik of dermatology and venereology. 2010;No.1:35–47. (In Russ).]
- Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis. J Immunol. 2018;201(6):1605–1613.
- Chan TC, Hawkes JE, Krueger JG. Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment. Ther Adv Chronic Dis. 2018;9(5):111–119.
- Yang L, Li B, Dang E, et al. Impaired function of regulatory T cells in patients with psoriasis is mediated by phosphorylation of STAT3. J Dermatol Sci. 2016;81(2):85–92.
- Bovenschen HJ, van de Kerkhof PC, van Erp PE, et al. Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol. 2011;131(9):1853–1860.
- Puig L. Guselkumab for the treatment of adults with moderate to severe plaque psoriasis. Expert Rev Clin Immunol. 2019;15(6):589–597.doi: 10.1080/1744666X.2019.1601014.
- Инструкция по медицинскому применению гуселькумаба ЛП-005686 от 28.05.2020. [Электронный ресурс]. http://grls.rosminzdrav.ru (Дата обращения: 28.07.2020).
- Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114–123. doi: 10.1111/bjd.15750.
- Reich K, Armstrong April W, Langley Richard G, Flavin S, Randazzo B, Li S, Hsu Ming-Chun, Branigan P, Blauvelt A. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial Lancet 2019;394:831–39.
- Late Breaking [Электронный ресурс]. № 81201238. С. 1–9. URL: https://www.events.mondial.at/ei/2018/Downloads/Late_Breaking_Abstracts_1–8.pdf.
- Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi YS, Shen YK. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator. J. Am. Acad. Dermatol. Elsevier Inc, 2017;Т.76:№3:P.405–417.
- Reich K, Armstrong AW, Foley P, Song M, Wasfi YS, Randazzo B, Li SZ, Shen, Gordon K.B. Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double‐blind, placebo‐ and active comparator–controlled VOYA. Journal of the American Academy of Dermatology. 2017;76:418–431.
- Griffiths CEM, et al. Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1. J Dermatolog Treat. 2020;Jul13;1–9. doi: 10.1080/09546634.2020.1782817. Online ahead of print.
- Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015;26(1):23–31. doi: 10.3109/09546634.2013.865009.
- Griffiths CEM. Fall Clinical Dermatology Conference; October 17–20,2019; Las Vegas, NV. www.mhra.gov.uk/yellowcard.
- Cameron C, Druchok C, Hutton B, McElligott S, Nair S, Schubert A, Situ A, Varu A, Villacorta R. Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis During Induction Phase: A Systematic Review and Network Meta-Analysis. Journal of Psoriasis and Psoriatic Arthritis. 2019;4:81–92.
- Griffiths CEM, Radtke MA, Youn SW, Bissonnette R, Song M, Wasfi Y, Randazzo B, You Y, Shen Y-K, Strober B. Clinical response after guselkumab treatment among adalimumab PASI 90 nonresponders: Results from the VOYAGE 1 and 2 trials. Journal of the American Academy of Dermatology, Volume 79, Issue 3, AB78.
- Lunder T, Puig L, Tsai TF, Bhutani T, Ramachandran P, Uy J, Song M, You Y, Gooderham M, Lebwohl M. Drug survival of biological therapy is showing class effect: updated results from Slovenian National Registry of psoriasis. Int. J. Dermatol. 2019. С. ijd.14429.
- Gordon KB, Armstrong AW, Foley P, et al. Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study. J Invest Dermatol. 2019;139(12):2437–2446.e1. doi: 10.1016/j.jid.2019.05.016.
- Puig L, Tsai TF, Bhutani T, Ramachandran P, Uy J, Song M, You Y, Gooderham M, Lebwohl M. Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and antituberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials Eur Acad Dermatol Venereol 2020 Apr 14. doi: 10.1111/jdv.16460.
- Armstrong April W, Puig L, Joshi A, et al. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis. JAMA Dermatol. 2020;156(3):258–269. doi: 10.1001/jamadermatol.2019.4029
- Клинические рекомендации. Псориаз. 2020. Доступно на: http://cr.rosminzdrav.ru/#!/schema/866 (Дата обращения: 23.07.2020). [Clinical guidelines. Psoriasis. 2020. Available at: http://cr.rosminzdrav.ru/#!/schema/866 (Date accessed: 23.07.2020) (In Russ).]
Supplementary files
